herceptinr

herceptinr compiles and organizes assay and genomic data to enable analysis of Trastuzumab (Herceptin) resistance mechanisms in HER2-positive breast cancer.

Key Features:

• Assay compendium: Contains data from approximately 2,500 assays conducted on various breast cancer cell lines (BCCs) focused on Herceptin resistance and sensitivity.
• Genomic integration: Integrates gene expression profiles, mutations, and copy number variations for the included BCCs.
• Resistance–sensitivity linkage: Links assay findings to genetic profiles to support investigation of genetic underpinnings of resistance.
• Biomarker resource: Provides data to support design of biomarkers predicting response to Trastuzumab (Herceptin).
• Combination therapy insights: Enables identification of supplementary drugs and combination strategies to enhance Herceptin sensitivity.

Scientific Applications:

• Mechanistic investigation: Study genetic mechanisms of Trastuzumab resistance in HER2-positive breast cancer.
• Biomarker development: Develop biomarkers to predict which patients are likely to benefit from Herceptin treatment.
• Combination therapy selection: Identify candidate supplementary drugs and combinations to overcome acquired or de novo resistance.
• Genotype–phenotype analysis: Analyze associations between gene expression, mutations, copy number variations and Herceptin sensitivity.

Methodology:

Compilation and integration of approximately 2,500 assays with genomic data (gene expression, mutations, and copy number variations) from breast cancer cell lines (BCCs).